gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BEAMHealthcareBiotechnology

Beam Therapeutics Inc. Common Stock (BEAM)

$27.79+5.54%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$26.33▲ 8.58% in range
Nov 3, 2025Low $20.60 · High $37.92Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Beam Therapeutics closed at $27.79 on Nov 4, up 5.54%, 26.7% below its 52-week closing high. Volume of 1.3M shares was 0.72× its 20-day average (below normal).

Split-adjusted performance: +10.1% over one month, -14.1% over six months, +14.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $490K, down 94.2% from a year earlier, with a net margin of -25036.3%.

Short interest was 26.2M shares at the Oct 15 settlement, down 4.7% from the prior report (32.0% of float, 14.1 days to cover).

Market cap$2.87B103.3M shares
Revenue · quarter$490.0K−94.2% YoY
Diluted EPS$-1.18—
P/E · TTM—P/S 18.4×
Net margin-25,036.3%Gross 100.0%
Dividend yieldNone$0.225 last paid
52-week range20.60 – 37.92−26.7% from high
Volume1.3M0.72× 20-day avg
Volatility · 60d64.2%Annualised
Short % of float32.0%14.1 days to cover
Net cash$1.05BCash $1.15B
Next earnings—Not scheduled
Split-adjusted performance
1W −3.4%1M +10.1%3M +2.0%6M −14.1%YTD +0.3%1Y +14.6%3Y +45.4%5Y −69.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum56
Revenue growth12
Net margin4
Value (low P/E)—
Size82

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short26.2M−4.7% vs prior
Days to cover14.1Settled Oct 15
% of float32.0%
Short vol. 10d60.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87B
TARSTarsus Pharmaceuticals$69.07−4.91%+6.7%+63.9%−343.5%—$3.23BCompare
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35BCompare
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11BCompare
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare

News about Beam Therapeutics

All news →
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Zacks Investment Research · 6d ago▲ PositiveBeam Therapeutics to Participate in Upcoming September 2026 Investor ConferencesGlobeNewswire Inc. · Aug 31, 2026▲ PositiveBetter Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?The Motley Fool · May 26, 2026NeutralBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceGlobeNewswire Inc. · May 18, 2026▲ PositiveBeam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.The Motley Fool · Apr 11, 2026▲ Positive

Quick answers

What does Beam Therapeutics do?
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104.
What is BEAM's market cap?
$2.87B, based on the Nov 4 close of $27.79.
Does Beam Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BEAM is sold short?
26.2M shares, 32.0% of float, as of Oct 15, 2026.
What sector is BEAM in?
Healthcare, in the Biotechnology industry.

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

HQ: Cambridge, MA540 employeesListed Feb 6, 2020beamtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology